Session » Rheumatoid Arthritis - Clinical Aspects Poster Session III

Date: Tuesday, November 10, 2015

Time: 9:00AM-11:00AM

Meeting: 2015 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 2605

14-3-3η Positive Status and Higher Titres Are Associated with More Severe RA

9:00AM-11:00AM: Abstract Number: 2682

A Brief Patient-Reported Measure of Physical Function Is Sensitive to Changes in a Composite Disease Activity Measure in a Diverse Rheumatoid Arthritis Clinic Setting

9:00AM-11:00AM: Abstract Number: 2656

Analysis of Morning Stiffness Response in Rheumatoid Arthritis Patients with Low Disease Activity Receiving Delayed-Release Prednisone Plus Dmards As Compared to Placebo Plus Dmards

9:00AM-11:00AM: Abstract Number: 2590

Anti-Citrullinated Protein Antibody and Radiographic Disease Progression in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2607

Anti-Cyclic Citrullinated Peptide Antibodies and Rheumatoid Factor in Rheumatoid Arthritis Hispanics Exposed to Biomass Smoke

9:00AM-11:00AM: Abstract Number: 2661

Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2684

Association Between Anxiety and Depression and Rheumatoid Arthritis Outcome: Results from an Inception Early Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2673

Association Between Anxiety and Depression and Rheumatoid Disease Severity: Results from an Established Rheumatoid Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2633

Association of Medication Beliefs, Self-Efficacy, and Adherence in a Diverse Cohort of Adults with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2589

Associations Between 49 Susceptibility SNPs and Disease Activity Including Radiographic Damage in Early Untreated Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2634

Associations Between Health Literacy, Ethnicity, Communication Quality and Beliefs about Medicines in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2595

Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year

9:00AM-11:00AM: Abstract Number: 2586

Cardiac Magnetic Resonance Imaging Reveals Myocardial Damage in Patients with Active Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2602

CCP Antibody Negativity Is Associated with Higher Fatigue in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2615

Changes in a Patient-Reported Measure of Physical Function, PF-10a, Are Most Strongly Associated with Changes in the Patient Global Assessment Portion of a Composite Measure of RA Disease Activity

9:00AM-11:00AM: Abstract Number: 2645

Changes in Clinical Disease Activity Index and Changes in Sleep Among RA Patients Initiating Disease Modifying Antirheumatic Drugs

9:00AM-11:00AM: Abstract Number: 2621

Characteristics of Histopathology and Clinical Course of 19 Cases That Developed a Lymphoproliferative Disease (LPD) during Methotrexate (MTX) Treatment.

9:00AM-11:00AM: Abstract Number: 2611

Circulating Monocyte Count Is Significantly Associated with Interstitial Pneumonia in Biologic-Naive Patients with Rheumatoid Arthritis: A Single-Center Prospective Cohort Study (Keio First-Bio Cohort Study)

9:00AM-11:00AM: Abstract Number: 2667

Clinical Characteristics and Health Outcomes of RA Patients Not Adequately Controlled By Current Treatment

9:00AM-11:00AM: Abstract Number: 2687

Clinical Significance of Patient-Reported Pain and Stiffness at Each Joint Level in the Evaluation of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2619

Clinical Usefulness of Periodic Detection of Serum 14-3-3Î· for Predicting Efficacy of Tocilizumab in RA

9:00AM-11:00AM: Abstract Number: 2655

Clinically Important Worsening (CIW) of RA Disease Activity Requiring an Increase in Therapy Can be Identified Using a Combined Patient and Physician Report of Flare

9:00AM-11:00AM: Abstract Number: 2693

Comparing Eight Year Clinical and Radiographic Outcome in Two Cohorts of Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2636

Comparison of Arterial Health in Patients with Rheumatoid Arthritis to a Population-Based Cohort

9:00AM-11:00AM: Abstract Number: 2670

Comparison of M-DAS and DAS28, Two Composite Scores for Prediction of Structural Damages in Rheumatoid Arthritis: Data from the Espoir Cohort

9:00AM-11:00AM: Abstract Number: 2683

Contribution of Subjective Patient Reported Components of Disease Activity Scores Differs in Disease Activity Measures and Their Changes over Time Are Closely Associated with Objective Measures

9:00AM-11:00AM: Abstract Number: 2641

Correlation of Rheumatologists’ Perceptions of RA Severity with Observed Disease Activity, Patient Impact and Treatment Patterns

9:00AM-11:00AM: Abstract Number: 2647

Correlations Between Personality Types, Disease Activity and Quality of Life in As and RA Patients

9:00AM-11:00AM: Abstract Number: 2587

CRP and 14-3-3η Are Each Associated with Joint Damage Progression, Their Titres Do Not Correlate and Are Better Predictors of Progression Together Than Alone

9:00AM-11:00AM: Abstract Number: 2623

DAS28-ESR and DAS28-CRP Are Not Exchangeable in Daily Clinical Practice: Data from a Large Outpatient Cohort

9:00AM-11:00AM: Abstract Number: 2643

Decreased Pain Level with Aging Leads to Underestimation of Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2672

Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States

9:00AM-11:00AM: Abstract Number: 2679

Development and Validation of a HAQ-Derived Tool to Detect Muscle Mass Deficits in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2632

Development and Validation of a Questionnaire Assessing the Fears and Beliefs of Patients Suffering from Chronic Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 2653

Diagnostic Value of the Prednisolone Test in Patients with Possible Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2646

Different Wording of the Patient Global Assessment Scale Leads to Different Rating of Disease Activity

9:00AM-11:00AM: Abstract Number: 2689

Discrepancies Between Patients and Physicians in Their Perceptions of Rheumatoid Arthritis Disease Activity Are Multifactorial in Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2626

Disease Activity Predicts ABCB1 and ABCG2 Drug-Efflux Transporters Function in Rheumatoid Arthritis (RA) Patients

9:00AM-11:00AM: Abstract Number: 2627

Does 14-3-3 ETA Protein Offer Any Additional Diagnostic Value in Rheumatoid Arthritis?

9:00AM-11:00AM: Abstract Number: 2668

Effect of Anti-Cyclic Citrullinated Peptide 2 Immunoglobulin M Serostatus on Efficacy Outcomes Following Treatment with Abatacept Plus Methotrexate

9:00AM-11:00AM: Abstract Number: 2660

Elevated 14-3-3η Serum Protein Levels Increase RA Confirmation Rates in Recent-Onset Polyarthritis Patients

9:00AM-11:00AM: Abstract Number: 2663

Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity

9:00AM-11:00AM: Abstract Number: 2604

Evaluation of Serum Undercarboxylated Osteocalcin in Premenopausal Rheumatoid Arthritis Patients; Its Correlation with Disease Activity and Bone Mineral Density

9:00AM-11:00AM: Abstract Number: 2651

Evaluation of the Impact of Disease-Modifying Antirheumatic Drugs on Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice

9:00AM-11:00AM: Abstract Number: 2640

Factors Influencing Treatment Adjustments in RA Patients – Biologic DMARD Treatment Start and Options

9:00AM-11:00AM: Abstract Number: 2597

Fine Specificity of Anti-Citrullinated Peptide Antibodies Is Associated with Left Ventricular Mass Index in Rheumatoid Arthritis Patients without Cardiovascular Disease

9:00AM-11:00AM: Abstract Number: 2664

Flares Occur Frequently in RA Patients Undergoing Arthroplasty

9:00AM-11:00AM: Abstract Number: 2696

Geography and Association Between Patient Reported Outcomes and Disease Activity (DAS28) Components in Patients with Rheumatoid Arthritis, Among 17 Countries

9:00AM-11:00AM: Abstract Number: 2675

Has the Relationship Between Disease Activity and Disability in Rheumatoid Arthritis Changed?

9:00AM-11:00AM: Abstract Number: 2685

High Levels of 25(OH)D Are Associated with Lower Disease Activity in Patients with Newly Diagnosed Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2628

Identifying Anxiety and Depression Among Rheumatoid Arthritis Patients Using the Multidimensional Health Assessment Questionnaire

9:00AM-11:00AM: Abstract Number: 2612

Impact of a Multibiomarker Disease Activity Score in Patients with Rheumatoid Arthritis Treated in a Real World Setting

9:00AM-11:00AM: Abstract Number: 2650

Impact of Patient Education on the Satisfaction of Rheumatoid Arthritis Patient : A Randomized Trial of Nurse-Led Vs. Physician-Led Education

9:00AM-11:00AM: Abstract Number: 2665

Improved Flare/ Remission Pattern in Rheumatoid Arthritis over the Recent Decades

9:00AM-11:00AM: Abstract Number: 2657

Influence of Anxiety and Depression on the Swollen to Tender Joint Count Ratio: In Pursuit of a Phenotype of RA Patients with Somatic Complaints in a U.S. Veteran Population

9:00AM-11:00AM: Abstract Number: 2676

Is It Useful to Determine All Rheumatoid Factors Isotypes to Enhance Rheumatoid Arthritis Detection? a Clinical Laboratory Perspective

9:00AM-11:00AM: Abstract Number: 2596

Less Musculoskeletal Ultrasound Power Doppler Activity Seen in Obese Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2658

Low Disease Activity Is Associated with Higher HDL and a Trend to Lower Insulin Resistance in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2671

Male Gender and Higher Hemoglobin Predict Response to Methotrexate in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2618

Methotrexate Dose May Associated with the Frequency of Lymphoproliferative Disorders in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2594

Multi-Biomarker Disease Activity Score As a Predictor of Flare in Patients with Rheumatoid Arthritis Who Stop TNF-Alpha-Inhibitor Therapy

9:00AM-11:00AM: Abstract Number: 2638

Multiple Psychosocial Factors Influence Subjective Assessments of Disease Activity in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2691

Musculoskeletal Ultrasound in Multi-Center Rheumatoid Arthritis Clinical Trials: Methodology for Optimizing Reliability of Acquisition and Real-Time Scoring

9:00AM-11:00AM: Abstract Number: 2598

Neutrophil Extracellular Trap Levels Measured By Cell Free Nucleosome ELISA in Serum Are Highly Specific and Sensitive for Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2686

No Clear Association Between the Presence of Ultrasound Synovitis and Patient Reported Outcomes in Rheumatoid Arthritis Patients in Remission

9:00AM-11:00AM: Abstract Number: 2674

Patient Global Assessment in Evaluating Boolean-Based Remission in Rheumatoid Arthritis-Is It Really Required Instead of Physician Global Assessment? a Comparative Study with Ultrasound

9:00AM-11:00AM: Abstract Number: 2642

Patient Reported Outcome Assessment of Rheumatoid Arthritis Patients Experience with IV Administered Biologic Therapy

9:00AM-11:00AM: Abstract Number: 2613

Patient Reported Physical Capacity Correlates with Phenylalanine Serum Levels in Patients with Early Untreated Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2669

Persistency of Patient Reported Morning (AM) Stiffness in a Large US Registry Cohort of Rheumatoid Arthritis (RA) Patients Initiating New DMARD Therapy

9:00AM-11:00AM: Abstract Number: 2697

Phenome-Wide Association Study of Rheumatoid Arthritis Subgroups Identifies Association Between Seronegative Disease and Fibromyalgia

9:00AM-11:00AM: Abstract Number: 2681

Physical Function, Sleep, Depression but Not CRP Level Is Associated with Fatigue in Patients with Established Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2659

Poor Correlation Between Vectra DA and DAS28 Scores in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2652

Power Doppler Ultrasound Features in Rheumatoid Arthritis Patients in Clinical Remission: Reclassifying Disease Activity?

9:00AM-11:00AM: Abstract Number: 2584

Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment

9:00AM-11:00AM: Abstract Number: 2620

Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis

9:00AM-11:00AM: Abstract Number: 2624

Preliminary Content Validation of the Patient Reported Outcomes Measurement Information System (PROMIS) Short Forms in People Living with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2637

Prevalence of Unacceptable Pain and the Risk of Fatigue and Sleeping Problems in Early Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2610

Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up

9:00AM-11:00AM: Abstract Number: 2593

Relationship Between Index of Activity Speed (Time Up and Go test) and Patient-Reported Outcome in Patients with Long-Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function

9:00AM-11:00AM: Abstract Number: 2630

Rheumatoid Arthritis Patients with Carotid Plaque: 10-Year Follow-up

9:00AM-11:00AM: Abstract Number: 2592

Rheumatoid Arthritis Patients with Many Autoantibodies Have Different Characteristics at Presentation Compared to Patients with Few Autoantibodies

9:00AM-11:00AM: Abstract Number: 2631

Rheumatologists More Likely to Perform Tobacco Cessation Counselling in Uncontrolled Rheumatoid Arthritis Visits

9:00AM-11:00AM: Abstract Number: 2625

SDAI 50 Is More Stringent Than the EULAR Response Measure and a Better Predictor of Low Disease State/Remission in Early Rheumatoid Arthritis: Results from an Early Arthritis Cohort

9:00AM-11:00AM: Abstract Number: 2585

Serum 14-3-3η Is an RA Specific Mechanistic Marker

9:00AM-11:00AM: Abstract Number: 2617

Serum 14-3-3eta Protein Elevation in Osteoarthritis Suggests Misclassification or Concurrent Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2606

Serum Myeloid Related Protein 8/14 Levels in Rheumatoid Arthritis: Marker of Disease Activity and Response to Methotrexate in DMARD Naïve Patients

9:00AM-11:00AM: Abstract Number: 2622

Serum RANKL Levels, Associate with Anti Citrullinated Proteins Antibodies (ACPA) in Early-Untreated Rheumatoid Arthritis and Is Modulated Following Methotrexate

9:00AM-11:00AM: Abstract Number: 2680

Severity of Morning Stiffness Is Associated More Strongly with Disease Activity in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2600

Signs of Immune Activation and Local Inflammation Are Present in the Bronchial Tissue of Patients with Untreated Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2614

Single Academic Center Experience with 14-3-3 Eta in the Evaluation of Inflammatory Arthritis

9:00AM-11:00AM: Abstract Number: 2688

Socioeconomic Status, Ethnicity/Race, and Autoantibody Status in Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2616

Study of Anti-Carbamylated Protein Antibody in the Rheumatoid Patients Who Were Clinically Active and Under Treatment with Biological Dmards

9:00AM-11:00AM: Abstract Number: 2588

Survivin Links Smoking and High Prevalence of Rheumatoid Arthritis in Women

9:00AM-11:00AM: Abstract Number: 2677

Targeting Biomarkers of Nitric Oxide and Endothelial Dysfunction in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2649

Test-Retest Reliability of the 5-Item Compliance Questionnaire Rheumatology and Factors Influencing Its Assessment of Adherence in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2695

Th17 Cell Related Cytokines and Microarray Expression Profiles in Patients with Early Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2608

The “Rheumatoid Arthritis Impact of Disease”� Score Correlates with Other Patient Reported Outcomes and with Disease Activity Scores in Patients with RA and Its Patient Acceptable Symptom State Is More Stringent Than DAS28-Remission

9:00AM-11:00AM: Abstract Number: 2599

The Effect of Daily Low Dose Prednisone (divided daily versus single daily dose) in the Treatment of African Americans (AA) with Early Rheumatoid Arthritis (RA)

9:00AM-11:00AM: Abstract Number: 2690

The Effects of Disease of the Joints on Modified Health Assessment Questionnaire Scores in Rheumatoid Arthritis Patients: A Retrospective Study Using the National Database of Rheumatic Diseases By Ir-Net in Japan

9:00AM-11:00AM: Abstract Number: 2654

The Influence of Patient Reported Morning Stiffness on Patient Global Assessment in Rheumatoid Arthritis Patients Not Achieving ACR/EULAR Boolean Remission in a Large US Registry

9:00AM-11:00AM: Abstract Number: 2609

The Measurement of the Skin Autofluorescence As an Indicator of Disease Progression in Rheumatoid Arthritis Patients

9:00AM-11:00AM: Abstract Number: 2629

The Most Frequent Fears and Beliefs of 226 Patients with Rheumatoid Arthritis or Spondyloarthritis, Using a Novel Questionnaire

9:00AM-11:00AM: Abstract Number: 2601

The Multi-Biomarker Disease Activity Score in a TNF Inhibitor Tapering Study in Rheumatoid Arthritis Patients: Predictive Value for Successful Tapering, Flaring and Radiographic Progression

9:00AM-11:00AM: Abstract Number: 2692

The Patients Evaluation of Pain and Disease Activity As Well As Improvement during One-Year Follow-up on Etanercept Treatment Is Highly Associated to Subjective Factors and Not to Objective Assessments Including Ultrasound

9:00AM-11:00AM: Abstract Number: 2644

The Relationship Between Disease Activity and Cognitive Impairment in Patients with Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2639

Towards Patient-Centeredness of the Treat-to-Target Paradigm: Development of a Framework for Evaluation of Patients with Rheumatoid Arthritis in the Setting of Patient-Physician Discordance

9:00AM-11:00AM: Abstract Number: 2666

Trajectories of EQ-5D in RA Patients Treated with Biologics Using the IORRA Cohort

9:00AM-11:00AM: Abstract Number: 2591

Ultrasound Residual Synovitis Has an Impact on the Time to Relapse in RA Patients Considered in Clinical Remission: A Real Life Study of 211 Patients

9:00AM-11:00AM: Abstract Number: 2635

Validating Arthroscopic Findings Using Histology, Status for Erosive Disease, and CRP in RA

9:00AM-11:00AM: Abstract Number: 2662

Validation of the Quickdash in the Assessment of Rheumatoid Arthritis Disease Activity

9:00AM-11:00AM: Abstract Number: 2694

Variations in the Metabolome in Response to Disease Activity of Rheumatoid Arthritis

9:00AM-11:00AM: Abstract Number: 2648

Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy

9:00AM-11:00AM: Abstract Number: 2678

Vitamin D Serum Level in Early Arthritis Patients: Association with Disease Activity, Disability and Severity in the Espoir Cohort

9:00AM-11:00AM: Abstract Number: 2603

What Is the Variability of HAQ over Time in Patients with Rheumatoid Arthritis Treated with Anti-TNF?

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].